Stock GNCAQ GENOCEA BIOSCIENCES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Genocea Biosciences, Inc.

Equities

GNCAQ

US3724274010

Market Closed - OTC Markets
Other stock markets
 15:09:18 23/04/2024 BST 		5-day change 1st Jan Change
0.000001 USD 0.00% Intraday chart for Genocea Biosciences, Inc. 0.00% 0.00%
2023 Genocea Biosciences, Inc. Went Out of Business CI
2023 Liquidation Plan Approved for Genocea Biosciences, Inc. CI

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Genocea Biosciences, Inc. Went Out of Business
First Amended Disclosure Statement Filed by Genocea Biosciences, Inc.
Disclosure Statement Approved for Genocea Biosciences, Inc.
Genocea Biosciences, Inc. Filed for Bankruptcy
Genocea Biosciences, Inc. Announces Resignation of Ali Behbahani from Board of Director
Genocea Biosciences To Wind Down Operations; Shares Fall
Genocea Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
Genocea Announces Plan to Explore Strategic Alternatives
Genocea Biosciences, Inc. Presents Encouraging Initial Data from GEN-011 Phase 1/2a Trial at AACR 2022
Genocea Biosciences, Inc. Auditor Raises 'Going Concern' Doubt
Genocea Biosciences, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2021
Genocea to Present Clinical and Preclinical Data at AACR Annual Meeting
John Lunger Joins Genocea Biosciences' Board of Directors
Genocea Biosciences Teams Up with Janssen to Explore Immunogenicity of Neoantigens
Genocea Biosciences, Inc. Enters into an R&D Collaboration and Option Agreement with Janssen Biotech, Inc
Genocea Biosciences Provides Corporate Update
Genocea Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021
Genocea Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021
Genocea Biosciences, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021
Genocea Biosciences : Doses First Patient in Trial of Solid Tumor Therapy; Shares Rise Pre-Bell
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. GNCAQ Stock
  4. News Genocea Biosciences, Inc.
  5. Other languages